Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company’s proprietary PDAOAI technology with advanced robotics from its collaboration with TechForce Robotics, targeting pharmaceutical, biotechnology, and advanced therapeutics companies seeking to modernize manufacturing through AI-driven workflows, digital quality systems, and intelligent automation.
According to Oncotelic, the platform supports electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. The company also highlighted progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. This launch underscores Oncotelic’s shift toward providing AI-enabled services to the broader industry, leveraging its expertise in drug development and manufacturing.
The platform’s significance lies in its potential to reduce human error, increase efficiency, and streamline regulatory compliance for GMP manufacturing. By combining PDAOAI’s machine learning capabilities with robotic automation, Oncotelic aims to offer a scalable solution for companies facing challenges in maintaining quality standards while accelerating production timelines. The collaboration with TechForce Robotics brings purpose-built robotics designed for pharmaceutical manufacturing, including sterile injectable environments.
Oncotelic, a clinical-stage biopharmaceutical company, focuses on oncology and immunotherapy products addressing high-unmet-need cancers and rare pediatric indications. The company’s pipeline includes drug candidates developed internally and through joint ventures. Notably, Oncotelic owns 45% of GMP Bio, a joint venture advancing its own pipeline under the leadership of CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. The company also develops PDAOAI for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic’s relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and ongoing development with TechForce Robotics.
TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys robotics and automation for service, hospitality, and pharmaceutical manufacturing applications. The partnership positions Oncotelic to offer end-to-end AI and robotics solutions, potentially lowering barriers for smaller biotech firms to access advanced manufacturing capabilities. The announcement at BIO 2026, a major industry conference, signals Oncotelic’s strategic pivot to become a service provider beyond its own drug development programs, which could open new revenue streams and partnerships.
For more information about Oncotelic, visit www.oncotelic.com. Details on TechForce Robotics are available at www.techforcerobotics.com. The full press release is accessible at https://ibn.fm/upnBW.
